Oncologists near North Bergen, NJ

Biography: Dr. Marina Kremyanskaya, MD is a Hematology Specialist who practices in New York, NY. She is 49 years old. Dr. Marina Kremyanskaya, MD is affiliated with Mount Sinai Hospital.

Care Philosophy: Multidisciplinary, respectful care of patients with GU cancers

Biography: Dr. Adriana Malone, MD is a Hematology Specialist who practices in New York, NY. She is 52 years old and has been practicing for 25 years. Dr. Adriana Malone, MD is affiliated with Mount Sinai Hospital.

Care Philosophy: At Moffitt Cancer Center, we are working tirelessly in the areas of patient care, research and education to advance one step further in fighting cancer. As a National Cancer Institute-designated Comprehensive Cancer Center, we are committed to the health and safety of our patients and dedicated to providing expert cancer care. From enhanced quality of life to complete remission, Moffitt is Florida's top choice aiming to achieve the best outcome for each patient.

Biography: Dr. Barbara T. Ma, is an Assistant Professor of Medicine at Weill Cornell Medicine and an Assistant Attending Physician at New York Presbyterian Hospital. Dr. Ma graduated with B.S. in Biomedical Engineering and M.S. in Biotechnology from Johns Hopkins University. She received her medical degree from New York Medical College. She completed her internal medicine training at Georgetown University Hospital and fellowship in Hematology/Oncology at NewYork-Presbyterian Hospital/Weill Cornell Medicine, where she also served as a chief fellow. Dr. Ma cares for patients with skin cancers, including melanoma. Her research focus is optimizing immunotherapy treatments for solid tumor patients with special interest on immunotherapy toxicities. She heads the Phase I unit and leads Cellular Therapy for Solid Tumors at Cornell. Dr. Ma is a recipient of the American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Young Investigator Award. She is a member of American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), Golden Humanism Honor Society (GHHS), and Society for Immunotherapy and Translational Research in Cancer.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience. We are devoted to providing services that are patient-centered and compassionate, and care for you as a person.

Care Philosophy: My goal, as a colon and rectal surgeon and as a surgical oncologist is to help my patients make informed decisions in their care and understand their disease process and treatment options, both surgical and non-surgical. I hope to help my patients find a better quality of life and to help them through their surgical experience (when necessary). I am lucky to work with a world renowned group of multidisciplinary specialists to help promote a multifaceted treatment plan for my patients, including radiation oncologists, medical oncologists, radiologists, pathologists, gastroenterologists, pelvic floor specialists, urologists, and interventional radiologists.

Care Philosophy: I am a physician-scientist working clinically and in the laboratory to develop curative treatment strategies for blood cancers.

Biography: Dr. Cora Sternberg is a leading international researcher and world expert in the field of medical oncology, genitourinary (GU) cancers, and drug development. As a key opinion leader in three different types of genitourinary cancers, Dr. Sternberg isknown for her influential work in developing novel therapies and targeted agents for the treatment of prostate, renal and bladder cancers.Dr. Sternberg helped develop the original M-VAC chemotherapy regimen, as well as the double-dose/high-dose/accelerated-dose M-VAC chemotherapy regimens in bladder and urothelial cancers. These treatments are the gold standard, saving many lives and decreasing suffering in patientswith these diseases.Additionally, Dr. Sternberg has served as principal investigator or been involved in numerous practice-changing studies for prostate cancer. These research efforts have led to the FDA approvals of abiraterone acetate and enzalutamide in advanced prostate cancer. Most recently, her publication in the New England Journal of Medicine (NEJM) demonstrated dramatic improvements in metastasis-free survival (MFS) in men with castration resistant prostate cancer (CRPC) without evidence of metastatic disease, but at high risk of developing metastases, a population for whom there were previously no approved therapeutics. This research led to the approval of enzalutamide in the M0 CRPC patient population.Dr. Sternberg has been instrumental in the development of the drug Pazopanib, an antiangiogenic targeted therapy, for advanced clear cell renal cell carcinoma. Dr. Sternberg served as lead investigator in the large phase 3 international study that demonstrated the efficacy, safety and tolerability of this drug in patients with metastatic kidney cancer, culminating in the FDA approval. She has also participated in the development of other antiagiogenic agents such as sunitinib, cabozantinib, tivozanib and dovitinib to treat renal cell cancer.At Weill Cornell Medicine and NewYork-Presbyterian Hospital, Dr. Sternberg will facilitate the continued growth and development of clinical and translational research programs in genitourinary (GU) malignancies, with a particular emphasis on expanding the breadth and depth of clinical and translational research. AsClinical Director of the Englander Institute for Precision Medicine (EIPM), Dr. Sternberg will develop strategies to incorporate genomic sequencing and precision medicine throughout the Weill Cornell Medicine and NewYork-Presbyterian healthcare network, including Lower Manhattan, Brooklyn and Queens. In addition to providing her clinical and research expertise in genitourinary oncology, Dr. Sternberg will work closely with Olivier Elemento, PhD, renowned computational biologist and Director of the EIPM, to develop novel strategies and apply precision oncology to optimize cancer prevention, detection and treatment across a variety of tumor types.Dr. Sternberg previously served as Chief of the Department of Medical Oncology at the San Camillo-Forlanini Hospital in Rome, Italy, and adjunct Professor of Oncology at La Sapienza University in Rome. A graduate of the University of Pennsylvania undergraduate and medical schools, Dr. Sternberg completed her fellowship and previously was on staff at Memorial Sloan Kettering Cancer Center.Dr. Sternberg has published approximately 400 articles in peer-reviewed publications,including more than 100 first-authored articles. She has co-edited six textbooks, guest edited six others, and has published over 80 book chapters. Dr. Sternberg has lectured extensively at universities and cancer symposia worldwide, having given approximately 750 invited talks atprestigious international venues.Throughout her career, she has served on the editorial boards of Critical Reviews in Hematology and Oncology, Annals of Oncology, and the Journal of Clinical Oncology, and she currently serves on the editorial boards of Oncology, European Urology, the Harvard Medical School Annual Report on Prostate Diseases, Kidney Cancer, Nature Clinical Practice Urology, and European Urology Oncology. Dr. Sternberg also serves as Reviewer for the New England Journal of Medicine, the Journal of Clinical Oncology, the Lancet Oncology and others.She currently serves as the Solid Tumor Editor for Critical Reviews in Hematology and Oncology, Section Editor for Urologic Oncology, Associate Editor for Bladder Cancer Clinical Trials Corner, Associate Editor and Genitourinary Oncology Editor for ESMO Open-Cancer Horizons, and Associate Editor for Frontiers in Oncology. Additionally, Dr. Sternberg previously served as Oncology Editor for the British Journal of Urology, Section Editor for Urologic Oncology, and Genitourinary Editor for the European Journal of Cancer.Dr. Sternberg's leadership in the field is further exemplified by the numerous international committees on which she has served. She was elected to three consecutive terms as Board Member and Executive Board Member of the European Organization for Research and Treatment of Cancer (EORTC) and elected to the nominating committee of the American Society of Clinical Oncology (ASCO) board of directors, currently serving a 3-year term.This document has been edited with the instant web content composer which can be found at htmleditor.tools - give it a try.

Care Philosophy: I realize how scary it can be to receive a life-threatening diagnosis, and firmly believe in taking the time to clearly communicate with my patients about the nature of their disease and their various treatment options. This can not only vastly improve our patients' experiences, but also their treatment outcomes, as an educated patient is able to make informed decisions about care and reclaim some of the autonomy that can be lost when coping with a cancer diagnosis. In the midst of all the cutting-edge science and technology that we offer, I find it extremely important to remember that it is the patient who is the center of it all. I genuinely care about my patients, and instilling a sense of hope, sharing a laugh, or a kind word can be as important as all the medical advances and state-of-the-art science.

Biography: Manuela Orjuela-Grimm is a molecular epidemiologist and pediatric oncologist whose research focuses on vulnerability (including social) to environmental exposures, gene-nutrient/ environment interactions during windows of susceptibility such as pregnancy, early childhood, adolescence and the development of later genetic and epigenetic changes contributing to poorer health outcomes in childhood and adolescence. She leads EpiRbMx, a long-standing case control/ case series study examining exposure to methyl donors, folate pathway metabolism and risk for retinoblastoma in collaboration with a multidisciplinary team of investigators including the Hospital Infantil de Mexico, the Hospital de Pediatria at the Instituto Mexicano de Seguro Social (IMSS), the Instituto Nacional de Salud Publica (INSP), and the University of Toronto. In collaboration with INSP researchers, Dr. Orjuela is involved in multiple studies examining the intersection between food security, folate-related dietary intake, dietary diversity and environmental exposures in central Mexico, and in immigrants in New York. Interests: social contributors to dietary exposures, gene-nutrient interactions; one carbon donor metabolism; methylation; nutrient and environmental exposures during early life and later genetic and epigenetic effects; dietary assessment in Mexico, in populations on the move in Latin America; effects of acculturation and early life migration on nutrient/ environmental exposures in US Latinos.

Biography: Dr. Diana Kirke, MD is an Oncology Specialist who practices in New York, NY. She is 46 years old and has been practicing for 20 years. Dr. Diana Kirke, MD is affiliated with Mount Sinai Hospital, Mount Sinai Morningside and Mount Sinai Queens.

Biography: Dr. Despina Siolas received her Bachelor of Science with summa cum laude honors from St. John's University. She attended medical school at Stony Brook University, where she was awarded the prestigious E-Trade Financial Scholarship from the Hellenic Medical Society of New York. In addition to her MD degree, Dr. Siolas is the recipient of a Doctor of Philosophy in Genetics from the State University of New York at Stony Brook for studies she conducted in the lab of Greg Hannon PhD, Howard Hughes Medical Institute Professor, at Cold Spring Harbor Laboratory. She completed her internal medicine residency training and hematology/oncology fellowship at NYU Langone Health. In addition to treating patients, Dr. Siolas conducts research on cancer genes that influence the immune microenvironment using preclinical models of pancreatic cancer and colon cancer. She has authored numerous publications and has received a prestigious Mentored Clinical Scientist Research Career Development Award (K08) from the National Institute of Health. She is a member of the American Society for Clinical Oncology, the American Association for Cancer Research, and American Medical Association, and Hellenic Medical Society.

Care Philosophy: The journey of every patient with cancer is tough We can help them through it with compassionate care and shared decision making Accepted Health Plan information is only as accurate as the most current information submitted. Prior to your appointment, it is advisable to verify with a physician office that they are still a participating provider.

Care Philosophy: As a full-time breast surgeon, Dr Rebecca Yang focuses exclusively on the care of women with malignant and benign breast disease with a comprehensive patient-centered approach. She has expertise in advanced surgical procedures including sentinel lymph node biopsies and nipple sparing mastectomies. She has a strong interest in the role of integrative therapy in the management and subsequent survivorship care planning for women with a diagnosis of breast cancer. Dr Yang is a proponent of advancing care through participation in appropriate clinical trials. Accepted Health Plan information is only as accurate as the most current information submitted. Prior to your appointment, it is advisable to verify with a physician office that they are still a participating provider.

Biography: Dr. Valentin Kolev, MD is an Oncology Specialist who practices in New York, NY. He is 50 years old. Dr. Valentin Kolev, MD is affiliated with Mount Sinai Queens, Mount Sinai Morningside and Mount Sinai Brooklyn.

Care Philosophy: I have always been exquisitely sensitive to the cultural and emotional aspects of being ill. Fortunately, due to innovative treatments as well as a change in the medical mindset, we are now able to approach cancer therapy with a goal of maximizing quality of life while at the same time controlling disease. In many areas of oncology, especially in advanced, difficult to treat cancers and metastatic disease, the key to pursuing therapy is individualizing treatment to the patient's personal ability to withstand therapy. Thinking of cancer as a chronic disease and gearing therapies to be sustainable and effective is among one of my most important goals as I move forward with our clinical research and cancer treatment programs.

Biography: Dr. Stein is an Associate Professor of Medical Oncology at Columbia University Medical Center. He is a recognized expert in field of genitourinary oncology treating patients with prostate, kidney, bladder and testicular cancers. He is also a member of the Experimental Therapeutics program, investigating novel therapies across all solid tumors. In addition to providing standard therapies for the treatment of genitourinary cancers such as hormonal therapy, molecularly targeted therapy and chemotherapy, Dr. Stein leads multiple investigator initiated and industry sponsored clinical trials. Dr. Stein has a particular interest in the development of novel immune therapies for the treatment of prostate cancer, both in men with early recurrence of prostate cancer as well as in men with more advanced prostate cancer. He is also helping to lead two national trials in kidney cancer sponsored by the National Cancer Institute. Dr. Stein received his B.S. in Molecular Biophysics and Biochemistry from Yale University. He earned his medical degree at New York Medical College, receiving the graduation award in oncology for his published research. He completed a residency in internal medicine at Montefiore Medical Center, and a fellowship in Hematology and Medical Oncology at Mount Sinai Medical Center. Prior to joining Columbia University, Dr. Stein practiced genitourinary oncology for 13 years at Rutgers University and has been an author on over 60 publications including guidelines for assessing the efficacy of new drugs in prostate cancer and recommendations for the use of immunotherapy to treat prostate cancer.

Biography: Aya Haggiagi, MD is an assistant professor of neurology at CUIMC, in the Division of Neuro-Oncology. Dr. Haggiagi is board certified in Neurology and Neuro-Oncology. She graduated with highest honors from the University of Al-Fateh School of Medicine in Tripoli, Libya. She subsequently completed a postdoctoral research fellowship in the Department of Pathology and Cell Biology at Columbia, under the mentorship of Dr. Michael Shelanski, where her research focused on biochemical and genetic changes in neurofibrillary tangle predominant dementia. Dr. Haggiagi then pursued her medicine internship training at Westchester Medical Center, followed by neurology residency at NewYork-Presbyterian/Columbia University Irving Medical Center. After residency, she completed a two-year fellowship in Neuro-Oncology at Memorial Sloan Kettering Cancer Center. Dr. Haggiagi was an attending physician and an investigator at Memorial Sloan Kettering Cancer Center prior to returning to NYP/CUIMC. She is the recipient of the Society for Neuro-Oncology 2017 Best Abstract Award. Her research interests include the development of clinical trials, precision medicine, and neurologic complications of immunotherapy.

Care Philosophy: Our mission is to treat every patient with compassion, healthcare excellence, and superior service. We aim to see every patient within 1 week of their first phone call and initiate treatment within 2 weeks of their first appointment. The incredible effort put forth by our office and hospital staff members as well as the extent of services offered through the Robert Wood Johnson Barnabas Health System allows us to make that happen. Our office also offers a preoperative educational service headed by our chief nurse practitioner, Jaimie Bell. Patients have expressed that it has been very beneficial in getting them mentally and emotionally ready for surgery. Accepted Health Plan information is only as accurate as the most current information submitted. Prior to your appointment, it is advisable to verify with a physician office that they are still a participating provider.

Biography: Dr. Monica Hayes, MD is an Oncology Specialist who practices in New York, NY. She is 54 years old and has been practicing for 28 years. Dr. Monica Hayes, MD is affiliated with Mount Sinai Morningside, Mount Sinai Queens and Mount Sinai Brooklyn.

Biography: Dr. Stephanie Blank, MD is an Oncology Specialist who practices in New York, NY. She is 59 years old and has been practicing for 31 years. Dr. Stephanie Blank, MD is affiliated with Mount Sinai Brooklyn, Mount Sinai Morningside and Mount Sinai Queens.

Biography: Dr. Samantha Cohen, MD is an Oncology Specialist who practices in New York, NY. She is 53 years old and has been practicing for 21 years. Dr. Samantha Cohen, MD is affiliated with Mount Sinai Queens, Mount Sinai Morningside and Mount Sinai Brooklyn.

Biography: Dr. Anupama Goel, MD is an Oncology Specialist who practices in New York, NY. She is 52 years old and has been practicing for 28 years. Dr. Anupama Goel, MD is affiliated with Mount Sinai Morningside and Mount Sinai Hospital.

Care Philosophy: Accepted Health Plan information is only as accurate as the most current information submitted. Prior to your appointment, it is advisable to verify with a physician office that they are still a participating provider.

Biography: Dr. Howard A. Fine was recently recruited to Weill Cornell to be the Founding Directorof the Brain Tumor Center in the Sandra and Edward Meyer Cancer Center and Associate Director for the Translational Research of the Weill Cornell Brain Tumor Center. He is also appointed as the Chief of the Division of Neuro-Oncology in the Department of Neurology.Dr. Fine received his medical degree at the Mount Sinai School of Medicine in New York City, completed an internship and residency in Internal Medicine at the University of Pennsylvania in Philadelphia, and a fellowship in Medical Oncology at the Dana-Farber Cancer Institute and Harvard Medical School in Boston. Dr. Fine founded and Directed the Dana-Farber Cancer Institute Center for Neuro-Oncology at Harvard Medical School, and the Neuro-Oncology Branch, at the National Institutes of Health. Dr. Fine most recently served as Chief of the Division of Hematology and Oncology and as Deputy Director of the New York University Cancer CenterDr. Fine has a 26 year history of clinical and research work exclusively devoted to patients with brain tumors. He has run a basic and translational science laboratory continuously for those 26 years and has been involved in well over 100 brain tumor clinical trials. Dr. Fine has authored over 200 scholarly articles, reviews and book chapters in subjects all devoted to neuro-oncology/ brain tumors.Dr. Fine welcomes patients with brain tumors who wished to seek his consultation, care, and/or clinical trials.

Care Philosophy: I prefer to look at my interactions with my patients as a partnership. We work together to improve their health, cure their cancer, manage their reflux, or make their breathing better. I strongly believe that patients need to be an active participant in their care, and the first step of that is making sure they understand what the clinical situation is, what I propose as a treatment plan,and what their expectations can be going forward. Accepted Health Plan information is only as accurate as the most current information submitted. Prior to your appointment, it is advisable to verify with a physician office that they are still a participating provider.

Biography: Dr. Abdul Khuwaja, MD is an Internist who practices in Astoria, NY. He is 75 years old and has been practicing for 50 years. Dr. Abdul Khuwaja, MD is affiliated with Mount Sinai Queens.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience. We are devoted to providing services that are patient-centered and compassionate, and care for you as a person.

Care Philosophy: I have expertise in stem cell / bone marrow transplantation, with over 25 years of experience in this field. I am the Associate Director of the Blood and Bone Marrow Transplant Program of New York Presbyterian Hospital - Cornell. and the Service Chief of the inpatient BMT clinical service. I have major interests in improving the overall safety and effectiveness of transplantation. I also have significant experience in the management of hematological malignancies such as leukemia, lymphoma, myeloma, myelodysplasia, as well as aplastic anemia. I enjoy teaching residents and fellows management of patients undergoing transplantation and I have published articles in this field. I also review articles for medical journals relating to stem cell transplantation.I am involved in multiple research trials related to BMT, both as a principal and co investigator and I have represented NYP Weill Cornell at the Cancer Alliance Clinical Trials Group, the Myeloproliferative Disease Research group, and the BMT Clinical Trials Network. However, my main love is caring for patients; I enjoy meeting them, guiding them through the transplant process, and having a true doctor patient relationship. I am committed to providing the best possible, state of the art care for my patients, with clear explanations and ongoing personal support through difficult situations.

Biography: Dr. Noah Cohen, MD is a General Surgery Specialist who practices in New York, NY. He is 42 years old and has been practicing for 15 years. Dr. Noah Cohen, MD is affiliated with Mount Sinai Queens, Mount Sinai Brooklyn and Mount Sinai Hospital.

Biography: Amer Assal MD is a board certified medical oncologist and hematologist who specializes in the use of autologous and allogeneic bone marrow stem cell transplantation for the treatment of multiple myeloma, leukemia, lymphoma, myelodysplastic syndromes and other bone marrow disorders. Dr. Assal completed his medical education and internal medicine training at NYU School of Medicine. He was also a hospitalist in the department of medicine at Memorial Sloan Kettering Cancer Center caring for patients with a variety of cancer diagnoses, including stem cell transplant patients. Dr. Assal completed a fellowship in hematology and medical oncology at Albert Einstein College of Medicine where he also served as chief fellow. He finally completed a fellowship in blood and marrow stem cell transplantation at Memorial Sloan Kettering Cancer Center. His research interests center around improving outcomes of stem cell transplantation and the diseases it is used to treat. He has a particular interest in immunotherapy and studying ways to harness the immune system to attack tumor cells, while at the same time decreasing the risk of graft versus host disease. He is also interested in studying therapeutic interventions to prevent and treat relapse of disease after stem cell transplantation. He has presented his research at several national conferences and was awarded an American Society of Hematology Abstract Achievement award for his research.

Biography: Dr. Lisa Roth is an Assistant Professor in the Departments of Pediatrics and Medicine at Weill Cornell Medicine. She is also the Director of the Adolescent and Young Adult Lymphoma Program at Weill Cornell Medicine/New York Presbyterian Hospital. Dr. Roth has been named the Charles, Lillian, and Betty Neuwirth Clinical Scholar in Pediatric Oncology. Dr. Roth completed her undergraduate work at Duke University. She received her medical degree from New York University School of Medicine. Dr. Roth conducted her residency at NewYork-Presbyterian/Weill Cornell and her fellowship in pediatric hematology/oncology at Memorial Sloan-Kettering Cancer Center and NewYork-Presbyterian where she served as chief fellow. Dr. Roth specializes in treating children, adolescents and young adults with lymphoma and leukemia. She is a member of the Children's Oncology Group and an active participant in Hodgkin lymphoma and non-Hodgkin lymphoma clinical trials. She is also a member of the Weill Cornell Center for Lymphoma, a group which is internationally recognized for it's leadership in the treatment of patients with lymphoma. Dr. Roth's research focuses on identifying new treatments for children with lymphoma. She is particularly interested identifying novel targeted therapies. Targeted therapies may be less toxic than conventional chemotherapy and may be able to rescue those patients with chemotherapy-resistant disease. Dr. Roth has been recognized for her work with awards from the National Institutes of Health (NIH), the Lymphoma Research Foundation, Hyundai Hope on Wheels Foundation, and the St. Baldrick's Foundation. For More Videos, please see below: OR-Live: Treating AYA Patients with Hodgkins Lymphoma (5/10/2017)https://www.youtube.com/watch?v=PT-Qwg2EvqgLymphoma Cancer Treatment NY - Weill Cornell Dr. Roth In the News: Taking Away the Toll (12/2015)http://www.nyrr.org/races-and-events/2016/nyrr-new-york-mini-10k/lisa-roth

Biography: Rohit K. Jain MD, MPH is an Associate Professor of Medicine at Weill Cornell Medicine and Attending Physician at NewYork-Presbyterian Hospital- Weill Cornell Medical Center. Dr. Jain earned his medical degree at Topiwala National Medical College and B.Y.L. Nair Charitable Hospital, Mumbai, India. He completed Internal Medicine Residency at Johns Hopkins University/Sinai Hospital of Baltimore and Hematology-Oncology Fellowship at Roswell Park Cancer Institute University at Buffalo, New York. After fellowship, Dr. Jain, joined the H. Lee Moffitt Cancer Center in Tampa, Florida as Assistant Professor, and was instrumental in building the bladder cancer program. Dr. Jain was selected as Castle Connolly "Top Doctor" for 2024, as well as one of America's Best Prostate Cancer Oncologist by Newsweek magazine in 2024. Dr. Jain was recruited to Weill Cornell Medicine (WCM) in 2024. He cares for patients with bladder (urothelial), kidney (renal), prostate and testicular cancers, with a major focus in urothelial cancers. His research interests are primarily in urothelial and prostate cancers. Dr. Jain is involved in biomarker research as well as developing innovative clinical trials for patients, and he has received funding from the National Cancer Institute (NCI).

Care Philosophy: My clinical interests include working with children with various blood disorders, such as sickle cell anemia, blood clotting disorders, and rare disorders called Myeloproliferative Neoplasms. I find it a privilege to be able to help families deal with their children's complex medical issues. By combining excellent, compassionate medical care with research aimed at improving outcomes and preventing disease-associated complications, I believe that we can make a difference for children with cancer and blood disorders.

Biography: Dr. Gulati obtained her medical degree from Seth G.S. Medical College and K.E.M. Hospital in Mumbai, India, followed by a pediatrics residency at SUNY Downstate Medical center. She completed my pediatric hematology/oncology fellowship at the joint program between New York-Presbyterian Hospital/Weill Cornell Medical Center and Memorial Sloan-Kettering Cancer Center. She then went on to complete a year of specialized training in Pediatric lymphoma and Histiocytosis at Baylor College of Medicine/Texas Children's Hospital Cancer and Hematology Centers in Houston, Texas. Dr. Gulati subsequently joined the lymphoma and histiocytosis team as an Assistant professor and worked there between 2019-2023.Dr. Gulati's research and clinical interests focus on identifying pathogenic mechanisms of pediatric lymphoma and histiocytosis through collaborative and comprehensive research projects that look at the histologic, molecular, and genomic features of these diseases with the ultimate goal of identifying potential novel therapeutic targets.Dr. Gulati is an active member of the pediatric non-Hodgkin lymphoma committee of the children's oncology group and serves as the vice-chair on the upcoming first of its kind trial for relapsed L.C.H. conducted by the C.O.G. She is an active member of the North American Consortium for Histiocytosis (NACHO) and a steering committee member of the INTO-HLH.

Biography: Nicholas Cacciola-Price, NP is a Radiation Oncology Specialist who practices in New York, NY. Nicholas Cacciola-Price, NP is affiliated with Newyork-Presbyterian.

Biography: Dr. Rosenzweig is an Assistant Professor in the Department of Pediatrics at Weill Cornell Medicine and an Assistant Attending Pediatrician at NewYork-Presbyterian/Weill Cornell Medical Center. Dr. Rosenzweig completed her undergraduate work at Emory University. She received her medical degree from the University of Miami Miller School of Medicine. She conducted her residency in Pediatrics at NewYork-Presbyterian/Weill Cornell Medical Center and her fellowship in pediatric hematology/oncology at the joint program at Memorial Sloan Kettering Cancer Center and NewYork-Presbyterian-Weill Cornell Medical Center. She is board certified in General Pediatrics and Pediatric Hematology/Oncology.Dr. Rosenzweig specializes in treating children and adolescents with leukemia and lymphoma, including acute lymphoblastic leukemia, acute myelogenous leukemia, Hodgkin lymphoma and Non-Hodgkin lymphoma.Dr. Rosenzweig's clinical and research interests lie in identifying new treatments for children with leukemia. She is particularly interested in identifying novel targeted therapies. She is a member of the Children's Oncology Group.

Biography: Dr. Shipra Kaicker is an Associate Professor of Clinical Pediatrics at Weill Cornell Medicine and Associate Attending Pediatrician at NewYork-Presbyterian Hospital. Her clinical areas of interest are pediatric hematology, platelet disorders, immune cytopenias, anemias, sickle cell disease and bone marrow failure syndromes. She is board certified in Pediatrics and Pediatric Hematology-Oncology. Dr. Kaicker received her M.B.B.S. degree at Lady Hardinge Medical College at the University of Delhi, New Delhi, India. She completed her M.D. and Pediatric Residency at Maulana Azad Medical College, also at the University of New Delhi, where she also served as Senior Registrar (Chief Resident) in Pediatrics. Dr. Kaicker expanded her training in New York City, where she completed a Post-Doctoral Clinical Fellowship and Post-Doctoral Research Fellowship, both in Pediatric Hematology-Oncology, at Columbia University Medical Center, and an additional Pediatric Residency at Saint Vincent's Medical Center. Dr. Kaicker is a clinical researcher and is participating in clinical trials for childhood immune thrombocytopenia as part of ICON ( ITP Consortium of North America) and collaborating with basic science researchers to identify biomarkers in childhood ITP

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience. We are devoted to providing services that are patient-centered and compassionate, and care for you as a person.

Biography: Dr. Catherine Shu isthe Price Family Associate Professor of Medicine anda board-certified medical oncologist specializing in the treatment of thoracic cancers, with a focus on lung cancer. She received her undergraduate degree from Princeton University, followed by her M.D. from Columbia University College of Physicians and Surgeons. After residency at Columbia University Medical Center, Dr. Shu completed her fellowship at Memorial Sloan Kettering Cancer Center, where she was appointed Chief Fellow. She currently serves as the Director of the Thoracic Medical Oncology Service. She has presented her work at numerous international conferences and has published in the top peer-reviewed oncology journals. She treats the entire spectrum of lung cancer, but has a particular interest in earlier stage and surgically resectable disease, specifically on drug combinations to help improve survival in this setting. Additionally, she devotes part of her research effort to patients with targetable mutations, helping to determine the best sequence of treatments. Of all her achievements, she is proudest to be able to offer individualized and compassionate care to each and every one of her patients. She understands that each patient and family carries forth a different set of beliefs, goals, and needs. Working alongside an exceptional multidisciplinary team, she is dedicated to improving the survival and bettering the quality of life of her patients.

Care Philosophy: "Better people means better experiences. Our care team is committed to delivering results that change lives."

Biography: Christina Russomanno, NP is a Nurse Practitioner who practices in New York, NY. She is 46 years old. Christina Russomanno, NP is affiliated with Newyork-Presbyterian/Columbia University Medical Center.

Biography: Ellen Cole, NP is a Nurse Practitioner who practices in New York, NY. Ellen Cole, NP is affiliated with Newyork-Presbyterian/Columbia University Medical Center.

Biography: Dr. Ingham is Assistant Professor of Medicine in the Division of Hematology and Oncology at New York Presbyterian Hospital/Columbia University Medical Center. He received his medical degree from the University of Massachusetts Medical School and completed internship and residency training in Internal Medicine at New York University Medical Center, where he served as Chief Resident. He then completed fellowship training in Hematology and Medical Oncology at New York Presbyterian Hospital/Columbia University Medical Center where he served as Chief Fellow. Dr. Ingham specializes in the care of patients with sarcoma and gastrointestinal cancers and is also an active member of the experimental therapeutics unit. His research focuses on the development and clinical evaluation of new treatments for patients with sarcoma. He leads a National Cancer Institute (NCI) sponsored clinical trial evaluating a new treatment approach for uterine leiomyosarcoma based on research conducted at Columbia University. He also leads several other investigator-initiated clinical trials evaluating new targeted and immunotherapy based treatment approaches for leiomyosarcoma, liposarcoma and other types of sarcoma. He is the author of two recent authoritative reviews on the treatment of sarcoma published in the Journal of Clinical Oncology. He is the recipient of the 2019 Conquer Cancer Foundation of ASCO Career Development Award from the Sarcoma Foundation of America in recognition of his research and was also named a 2019 NextGen Innovator by HemOnc Today, among other awards and honors. His overall goal is to provide patients with compassionate oncologic care and access to the most promising treatment approaches.

Biography: Rajshekhar Chakraborty, MD is an assistant professor of medicine at Columbia University Irving Medical Center in the division of hematology/oncology. After receiving his medical degree from University of Delhi, India, he completed his residency in internal medicine at Icahn School of Medicine at Mount Sinai-Queens Hospital Center. Subsequently, he spent three years as a clinical researcher in plasma cell disorders at the Mayo Clinic, Rochester, followed by fellowship in hematology/oncology at the Cleveland Clinic. During fellowship, he conducted outcomes research with a focus on quality of life and treatment-related toxicities in plasma cell disorders. After fellowship, he started his job as Assistant Professor of Medicine at the Multiple Myeloma and Amyloidosis Program at Columbia University Irving Medical Center. Dr. Chakraborty cares primarily for patients with plasma cells disorders, including multiple myeloma, amyloidosis, MGUS, POEMS syndrome, and Waldenstrom's macroglobulinemia. His research interests include clinical trials and outcomes research in plasma cell disorders.